GlassScriptPhysician profile
Kathyayini J Konuru
NPI 1124213756
$5,547.91
in general payments reported to CMS, 2019-2025
33 companies · $980 in 2025
The $980 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $284 · 2021: $633 · 2022: $863 · 2023: $1,227 · 2024: $899 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,062.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $839.49 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $529.19 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $501.78 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $346.17 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $269.93 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.10 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $260.36 | 2019-2022 | |
| Abbvie INC. | $252.61 | 2021-2025 | |
| Boston Scientific Corporation | $194.39 | 2023-2025 | Watchman Flx, Watchman Access System |
| Astellas Pharma US INC | $162.62 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $140.83 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.75 | 2019-2024 | Xifaxan |
| Abbott Laboratories | $74.87 | 2021-2024 | Freestyle Libre, Freestyle Libre 3 |
| Pfizer INC. | $73.96 | 2019-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $56.40 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $41.60 | 2019 | |
| Exact Sciences Corporation | $41.07 | 2023-2025 | Cologuard Collection Kit |
| Mannkind Corporation | $40.76 | 2019 | |
| Inspire Medical Systems, INC. | $38.77 | 2023 | Inspire |
| Xeris Pharmaceuticals, INC. | $36.04 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $30.50 | 2020-2021 | |
| Allergan, INC. | $23.35 | 2020 | |
| Bausch Health US, LLC | $21.89 | 2023 | Aplenzin |
| Biohaven Pharmaceuticals, INC. | $20.07 | 2021 | |
| Smith+Nephew, INC. | $20.03 | 2022 | |
| Corcept Therapeutics | $19.18 | 2023 | Korlym |
| Verity Pharmaceuticals INC. | $18.61 | 2025 | Tlando |
| Ethicon INC. | $17.49 | 2024 | Monarch Platform |
| Nestle Healthcare Nutrition INC. | $16.03 | 2021 | |
| Global Blood Therapeutics, INC. | $14.74 | 2022 | |
| Amarin Pharma, INC. | $14.51 | 2019 | |
| Hologic Sales and Service, LLC | $13.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathyayini Konuru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.